Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of ABSK021 in tenosynovial giant cell tumor
CTR20223301Phase 3Active
- Sponsor
- Abbisko Therapeutics
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pimicotinib in tenosynovial giant cell tumor (TGCT), sponsored by Abbisko Therapeutics. Started Apr 2023; status: active.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on CTR20223301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223301.